Print

AVEG 016A

A Phase I , Multicenter, Randomized, Double-blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of Low Dose MN RSGP 120/HIV-1 in Combination with QS21 Adjuvant or Alum in Healthy Adults

Trial Details:

I Completed
National Institute of Allergy and Infectious Diseases (NIAID) May 17, 1994
MN rgp120 Env gp120 B
MN rgp120 Protein
QS21
USA 118
NCT00001052
https://clinicaltrials.gov/show/NCT00001052